REFERENCES
- Parfrey PS. Cardiac disease in dialysis patients: diagnosis, burden of disease, prognosis, risk factors and management. Nephrol Dial Transplant 2000; 15(Suppl. 5)58–68
- London GM, Drüeke TB. Atherosclerosis and arteriosclerosis in chronic renal failure. Kidney Int 1997; 51: 1678–1695
- Jones CA, Krolewski AS, Rogus J, Xue JL, Collins A, Warram JH. Epidemic of end-stage renal disease in people with diabetes in the United States population: do we know the cause?. Kidney Int 2005; 67: 1684–1691
- Wilde C. Diabetic nephropathy—who cares?. EDTNA ERCA J 2004; 30: 163–165
- Borawski J, Mysliwiec M. The hematocrit-corrected erythrocyte sedimentation rate can be useful in diagnosing inflammation in hemodialysis patients. Nephron 2001; 89: 381–383
- Bayes B, Pastor MC, Bonal J, Romero R. “New” cardiovascular risk factors in patients with chronic kidney disease: Role of folic acid treatment. Kidney Int 2005; 67(Suppl. 93)39–43
- Busch M, Franke S, Muller A, et al. Potential cardiovascular risk factors in chronic kidney disease: AGEs, total homocysteine and metabolites, and the C-reactive protein. Kidney Int 2004; 66: 338–347
- Wanner C, Metzger T. C-reactive protein a marker for all-cause and cardiovascular mortality in hemodialysis patients. Nephrol Dial Transplant 2002; 17(Suppl. 8)29–32
- Iseki K, Tozawa M, Yoshi S, Fukiyama K. Serum C-reactive protein (CRP) and risk of death in chronic dialysis patients. Nephrol Dial Transplant 1999; 14: 1956–1960
- Stenvinkel P, Alvestrand A. Inflammation in end-stage renal disease: sources, consequences, and therapy. Semin Dial 2002; 15: 329–337
- Arici M, Walls J. End stage renal disease, atherosclerosis, and cardiovascular mortality: Is C-reactive protein the missing link?. Kidney Int 2001; 59: 407–414
- Freda BJ, Tang WH, Van Lente F, Peacock WF, Francis GS. Cardiac troponins in renal insufficiency: review and clinical implications. J Am Coll Cardiol 2002; 40: 2065–2071
- Bodor GS, Porterfield D, Voss EM, Smith S, Apple FS. Cardiac troponin I is not expressed in fetal and healthy or diseased adult human skeletal muscle tissue. Clin Chem 1995; 41: 1710–1715
- McLaurin MD, Apple FS, Falahati A, Murakami MM, Miller EA, Sharkey SW. Cardiac troponin I and creatine kinase-MB mass to rule out myocardial injury in hospitalized patients with renal insufficiency. Am J Cardiol 1998; 82: 973–975
- Iliou MC, Fumeron C, Benoit MO, et al. Factors associated with increased serum levels of cardiac troponins T and I in chronic hemodialysis patients: Chronic Hemodialysis and new Cardiac Markers Evaluation (CHANCE) study. Nephrol Dial Transplant 2001; 16: 1452–1458
- Lowber C, Stenvinkel P, Pecoits-Filho R, et al. Elevated cardiac troponin T in predialysis patients is associated with inflammation and predicts mortality. J Intern Med 2003; 253: 153–160
- Koch M, Kutkuhn B, Trenkwalder E, et al. Apolipoprotein B, fibrinogen, HDL cholesterol, and apolipoprotein(a) phenotypes predict CAD in hemodialysis patients. J Am Soc Nephrol 1997; 8: 1889–1898
- De Lemos JA, Hillis LD. Diagnosis and management of coronary artery disease in patients with end-stage renal disease on hemodialysis. J Am Soc Nephrol 1996; 7: 2044–2054